Home Cart Sign in  
Chemical Structure| 1231930-82-7 Chemical Structure| 1231930-82-7

Structure of Abemaciclib methanesulfonate
CAS No.: 1231930-82-7

Chemical Structure| 1231930-82-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Abemaciclib methanesulfonate is a selective CDK4/6 inhibitor with high affinity for CDK4/6, inhibiting CDK4/CDK6 with IC50 values of 2 nM and 10 nM, respectively. Abemaciclib methanesulfonate exhibits antitumor activity and is primarily used in the research and treatment of breast cancer and other CDK4/6-dependent cancers.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Abemaciclib methanesulfonate

CAS No. :1231930-82-7
Formula : C28H36F2N8O3S
M.W : 602.70
SMILES Code : CC1=NC2=C(F)C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=C2N1C(C)C.CS(=O)(O)=O
MDL No. :MFCD25562906
InChI Key :NCJPFQPEVDHJAZ-UHFFFAOYSA-N
Pubchem ID :71576678

Safety of Abemaciclib methanesulfonate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Abemaciclib methanesulfonate

Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 cells 10 µM 24, 48 or 72 h Abemaciclib induced more cytotoxicity than P2shortA in A549 cells. PMC7019173
H358 cells 10 µM 24, 48 or 72 h P2short was more potent than Abemaciclib in all NSCLC cell lines. PMC7019173
PC9 cells 10 µM 24, 48 or 72 h P2short was more potent than Abemaciclib in all NSCLC cell lines. PMC7019173
MCF7 500 nM 7 days Abemaciclib induced widespread chromatin remodeling in MCF7 cells, evidenced by new regions of both significantly increased (“up-peaks”) and decreased (“down-peaks”) chromatin accessibility. PMC8115221
MDA-MB-453 500 nM 7 days Abemaciclib induced widespread chromatin remodeling in MDA-MB-453 cells, evidenced by new regions of both significantly increased (“up-peaks”) and decreased (“down-peaks”) chromatin accessibility. PMC8115221
BJ human primary fibroblasts 1 μM 8 days Abemaciclib induced cell cycle arrest, characterized by reduced RB phosphorylation, downregulation of E2F2, and increased p16 gene expression, leading to decreased cell proliferation and EdU incorporation. PMC8922251
WI38 human primary fibroblasts 1 μM 8 days Abemaciclib induced cell cycle arrest, characterized by decreased cell proliferation. PMC8922251
MCF7 cells 100 nM To investigate the inhibitory effect of Abemaciclib on CDK4 and CDK6 kinase activity, results showed that Abemaciclib significantly inhibited CDK4 kinase activity but had a weaker effect on CDK6 PMC8831444
MCF7 FAT1-loss cells 100 nM To investigate the inhibitory effect of Abemaciclib on CDK4 and CDK6 kinase activity, results showed that Abemaciclib significantly inhibited CDK4 kinase activity but had a weaker effect on CDK6 PMC8831444
HCC1428-LTED-AbemaR cells 250 nM 6-12 months To evaluate the anti-tumor activity of Abemaciclib in CDK4/6 inhibitor-resistant cells, results showed that Abemaciclib could still inhibit cell proliferation in resistant cells. PMC6921513
MCF7-LTED-Y537S-AbemaR cells 250 nM 6-10 months To evaluate the anti-tumor activity of Abemaciclib in CDK4/6 inhibitor-resistant cells with ESR1 mutations, results showed that Abemaciclib could still inhibit cell proliferation in resistant cells. PMC6921513
MCF7 0.1 μM to 20 μM 6 months To construct Abemaciclib-resistant cell lines and found that PARP1 and p-YB-1 were significantly upregulated in resistant cells. PMC10687910

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice A375 BRAF-mutated melanoma xenograft model Oral 45 or 90 mg/kg Single dose To assess the time course of abemaciclib-mediated target engagement and cell cycle arrest in A375 xenograft tumours. PMC4800303
Mice ccRCC xenograft model Oral gavage 60 mg/kg Twice daily for 25 days To evaluate the antitumor activity of Abemaciclib in a ccRCC xenograft model, results showed that Abemaciclib significantly suppressed tumor growth. PMC6913182
Mice H358 lung cancer model Oral 10 mg/kg Once daily for three weeks The combination of Abemaciclib and P2shortA significantly inhibited the growth of H358 lung cancer. PMC7019173
Mice PDX model Oral 90 mg/kg Daily for 21 to 28 days Abemaciclib treatment significantly increased H3K27ac marks in the PDX model, indicating chromatin remodeling also occurs in vivo. PMC8115221
Mice p16-3MR mice Intraperitoneal injection 50 mg/kg Once daily for 7 days Abemaciclib induced normal cells to enter a senescent state in vivo without toxicity, and did not affect, blood cell counts, or physical performance in mice. PMC8922251
Mice CDK6-high cell-derived xenografts Intraperitoneal injection 25 mg/kg 3 consecutive days To evaluate the antitumor effect of BSJ-05-017 in CDK6-high tumor models, results showed that BSJ-05-017 significantly inhibited tumor growth PMC8831444
Nude mice MDA-MB-231 or MCF7AR cell xenograft model Oral and intraperitoneal injection 100 mg/kg Three times a week, continuous treatment To verify the synergistic antitumor effect of Abemaciclib combined with LJI308 on xenograft tumors, significantly inhibiting tumor growth. PMC10687910

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.66mL

0.33mL

0.17mL

8.30mL

1.66mL

0.83mL

16.59mL

3.32mL

1.66mL

References

 

Historical Records

Categories